Chiron Initiates Phase I Trial in Skin Cancer
Posted on: Thursday, 13 April 2006, 06:00 CDT
US biotech Chiron Corporation has initiated a phase I clinical trial of its investigational drug CHIR-265, a selective Raf kinase inhibitor, in patients with skin cancer.
The single-agent, open-label phase I study of CHIR-265 is designed to evaluate the safety, dose tolerability and pharmacokinetic profile of CHIR-265 in patients with melanoma - a type of skin cancer.
According to the company, a translational medicine approach will be used to monitor biomarkers in order to evaluate the biological activity and define the optimal dose. The study is expected to enroll up to 60 patients at three leading cancer centers in the US.
"We are pleased to move forward with clinical study of this exciting new compound," said Stephen Dilly, chief medical officer, Chiron BioPharmaceuticals. "Malignant melanoma is a promising indication for CHIR-265, given the high percentage of Raf mutations associated with the disease and the need for effective new treatments."
Preclinical data suggest that CHIR-265 has both direct anti-proliferative/pro-apoptotic activity on tumor cells as well as anti-angiogenic activity that targets the tumor blood supply.
Source: Datamonitor
Related Articles
- The Center for the Biology of Chronic Disease Highlights Anti-Cancer Activities of the Food Extracts Quercetin, EGCG, Glycyrrhizin, and Trans-Cinnamaldehyde
- Marshall Edwards' Phenoxodiol and Novogen's NV-128 Display Divergent Mechanisms of Action but Potent Synergistic Anti-Cancer Activity When Used in Combination
- Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months
- The International Journal of Cancer Publishes Studies on the Anti-Cancer Activity of Generex Biotechnology's Immunotherapeutic Vaccine
- Study Shows Ixabepilone Demonstrated Clear Activity in Patients With Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
- Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B(R) Showed Significant Reductions in Disease Activity in Patients With Active Systemic Lupus Erythematosus
- Data From ArQule's Phase 1 Trial With C-Met Inhibitor, ARQ 197, Demonstrate Safety and Expanded Anti-Cancer Activity
- Encouraging Results of a Clinical Study With GSK's Novel Cancer Immunotherapy Report Activity in Patients With Most Common Form of Lung Cancer
- Vitamin D lowers cancer risk: study
- Breast Cancer Prevention Study Spotlights Debate Over Drug Trials
 |
 |
User Comments (0)
RSS Feeds